Drug Database
RH

Rho(D) Immune Globulin

✓ Approved

CSL Limited · Polyclonal Antibodies · Polyclonal Antibodies

What is Rho(D) Immune Globulin?

Rho(D) Immune Globulin is a polyclonal antibodies developed by CSL Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyCSL Limited
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, CSL Limited

Therapeutic Indications

Rho(D) Immune Globulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Aplastic anemia developed after treatment with durvalumab].

Maeshima Kaho K, Sakayori Yo Y, Yokoyama Hiroki H, Katsube Atsushi A et al.

A 76-year-old woman with stage IIIB squamous cell lung carcinoma developed pancytopenia following maintenance therapy with durvalumab. She was diagnosed with squamous cell lung carcinoma (T4N2M0, stageIIIB) in December 2023. Following a favorable response to chemoradiotherapy, maintenance therapy with durvalumab was initiated in June 2024. Thrombocytopenia was observed starting in August, and platelet count had decreased to 22,000/µl in October, leading to the discontinuation of durvalumab. However, the condition progressed to pancytopenia. Bone marrow biopsy revealed hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis. Additional findings included paroxysmal nocturnal hemoglobinuria-type blood cells and fatty marrow replacement on spinal MRI. Based on these comprehensive findings, the patient was diagnosed with aplastic anemia (AA) in January 2025. Immunosuppressive therapy combining antithymocyte globulin, cyclosporine A, and eltrombopag was initiated in February 2025, resulting in a favorable response. AA is a relatively rare immune-related adverse event, and reports of AA induced by durvalumab are extremely limited. This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy.

PMID 42669502
Read full article →
PubMedCureus2026-08-30

Association of Vitamin D Deficiency With Cardiometabolic and Renal Outcomes in Patients With Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.

Imran Adnan A, Waris Hafiz Abdul HA, Khan Tanoli Sikander S, Raza Muhammad Tabish MT et al.

Autoimmune rheumatic diseases (ARDs) are chronic immune-mediated diseases associated with increased cardiovascular and renal morbidity. Vitamin D deficiency is common in these disorders and may coexist with inflammation, immune dysregulation, endothelial dysfunction, and impaired vascular and renal homeostasis. This systematic review and meta-analysis evaluated the association of vitamin D deficiency with adverse cardiometabolic and renal outcomes in ARDs. PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar were searched from inception through March 31, 2026, without language restrictions. Observational studies that measured serum 25-hydroxyvitamin D (25(OH)D) and reported cardiometabolic, cardiovascular, renal, or cardiorenal outcomes were eligible. Two reviewers independently conducted study selection, data extraction, and quality assessment. Compatible outcome-specific estimates were pooled using constrained maximum-likelihood random-effects models with Hartung-Knapp inference. Hazard ratios (HRs) and correlation coefficients were examined independently. Eighteen studies met the eligibility criteria, and four independent cohorts contributed to at least one quantitative synthesis. Vitamin D deficiency was associated with higher all-cause mortality (pooled HR 1.95, 95% confidence interval (CI) 1.36-2.79). The pooled association with cardiovascular events was imprecise (HR 2.20, 95% CI 0.52-9.25). Serum 25(OH)D was inversely but inconclusively correlated with proteinuria in pediatric systemic lupus erythematosus (r = -0.47, 95% CI -0.98 to 0.85). Cardiometabolic studies generally reported adverse metabolic and vascular findings but could not be pooled because of incompatible effect measures. Vitamin D deficiency was associated with higher mortality and greater cardiometabolic and renal disease burden; however, cardiovascular-event and proteinuria estimates remained inconclusive. Observational designs, residual confounding, heterogeneous definitions, and few compatible studies precluded causal conclusions. Prospective studies and randomized trials are required to determine whether correcting vitamin D deficiency improves clinical outcomes.

PMID 42668756
Read full article →
PubMedParasite epidemiology and control2026-08-30

Co-infection with Schistosoma mansoni and Helicobacter pylori: epidemiological patterns and implications for integrated control.

Ahmed Ashraf Fawzy Mosa AFM, Ali Hala Shehata HS, Alhussainy Nabeel H NH, El-Wahsh Hany M HM et al.

Co-infections with Schistosoma mansoni and Helicobacter pylori are frequently reported in low-resource endemic settings; however, their combined systemic and hematological effects in true co-endemic populations remain incompletely characterized. While S. mansoni transmission is primarily driven by exposure to agricultural water, H. pylori reflects persistent household and sanitation-related transmission, highlighting distinct yet overlapping epidemiological pathways. This study aimed to assess the association between occupational freshwater exposure and S. mansoni infection and to evaluate the clinical, hematological, and biochemical profiles associated with S. mansoni and H. pylori mono- and co-infections in a rural Egyptian population. A community-based, cross-sectional study was conducted in a rural agricultural village in Egypt. Participants were stratified into four groups: S. mansoni mono-infection (Gp1), S. mansoni-H. pylori co-infection (Gp2), H. pylori mono-infection (Gp3), and uninfected controls (Gp4). Clinical assessment, stool microscopy using the Kato-Katz thick smear technique, H. pylori coproantigen ELISA, complete blood counts, and serum biochemical analyses were performed. Comparative statistical analyses were used to evaluate group differences and associated risk factors. Occupational exposure (farm work) was strongly associated with S. mansoni infection (P < 0.001), reinforcing its role as a key transmission driver in rural endemic settings. Gastrointestinal symptoms were largely non-specific, although hematochezia occurred exclusively among individuals infected with S. mansoni. Co-infection did not significantly influence H. pylori antigen levels (P = 0.190), indicating limited biological interaction between the pathogens. Systemic alterations were predominantly driven by S. mansoni, including thrombocytopenia and marked eosinophilia (P < 0.001), alongside elevated serum globulin levels (P = 0.037), suggesting sustained immune activation. Other biochemical parameters showed no significant differences. In endemic rural settings, co-infection with S. mansoni and H. pylori does not demonstrate synergistic systemic effects but rather reflects overlapping transmission pathways with distinct epidemiological determinants. These findings suggest that integrated screening strategies may offer limited additional clinical benefit beyond pathogen-specific management, while still supporting coordinated control efforts targeting shared risk environments.

PMID 42668635
Read full article →
PubMedJournal of blood medicine2026-08-30

Clinical Outcomes of Rh(D)-Incompatible Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Retrospective Case Series with a Narrative Literature Review.

Liu Miaomiao M, Lin Min M, Fu Weijia W, Wang Ziwei Z et al.

Rh(D)-negative individuals are relatively rare in the Chinese population, and clinical experience with Rh(D)-incompatible allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains limited. Compared with ABO incompatibility, the immunohaematological consequences of Rh(D) mismatch in allo-HSCT are less well defined. Herein, we report a single-centre retrospective case series of four patients receiving Rh(D)-incompatible allo-HSCT at our institution, including two Rh(D)-negative recipients with Rh(D)-positive donors and two Rh(D)-positive recipients with Rh(D)-negative donors. We systematically evaluated post-transplant transfusion strategies, haematological recovery, anti-D alloantibody seroconversion, haemolysis or graft-versus-host disease (GVHD), and long-term survival outcomes. During a median follow-up of 36 months (range, 24-48 months), none of the patients developed detectable anti-D alloantibodies. Only one patient exhibited laboratory evidence of subclinical haemolysis responsive to low-dose prednisone, and another patient developed grade II acute gastrointestinal GVHD controlled by immunosuppressive agents. Nevertheless, all patients achieved sustained haematological engraftment without transplant-related mortalities. Combined with data from a narrative literature review, our single-centre observations are consistent with prior studies showing low risks of clinically significant haemolysis and anti-D alloimmunisation after Rh(D)-incompatible allo-HSCT. Rh(D) mismatch does not appear to be associated with severe transplant complications in our limited cohort, but these findings cannot be generalised broadly given the extremely small sample size. Rigorous peri-transplant transfusion management and regular post-transplant serological monitoring are still mandatory for Rh(D)-mismatched recipients.

PMID 42668990
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

Abe Shintaro S, Izumi Shintaro S, Tsukamoto Shokichi S, Miyamoto Izumi I et al.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for blast-phase myeloproliferative neoplasms (BP-MPN), although relapse rates remain high. Recently, conditioning with thiotepa, busulfan, and fludarabine (TBF) has shown promising anti-leukemic activity in acute myeloid leukemia. A 64-year-old man with essential thrombocythemia that progressed to secondary myelofibrosis and subsequently BP-MPN underwent allo-HSCT after cytoreduction with azacitidine plus venetoclax. Peripheral blood stem cells were obtained from an HLA allele-matched unrelated donor, and TBF was used as the conditioning regimen. Low-dose anti-thymocyte globulin was administered for graft-versus-host disease (GVHD) prophylaxis. Full donor chimerism was achieved on day 28 after transplantation. Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) improved with defibrotide, and acute GVHD was manageable. This case suggests that a multidisciplinary treatment strategy incorporating TBF conditioning may improve relapse-free survival in patients with BP-MPN.

PMID 42669508
Read full article →
PubMedPediatric research2026-08-30

A recombinant fragment of human surfactant protein D reduces lung inflammation in preterm lambs.

Castillo-Hernandez Tania F TF, Finkielsztein Ariel A, Bhatt Reena R, Panichi Daniele D et al.

Bronchopulmonary dysplasia (BPD), the major chronic respiratory morbidity in extremely preterm infants, is largely driven by inflammation. Preterm lungs are deficient of surfactant protein D (SP-D), an immunomodulatory protein absent in current commercial surfactant preparations. We hypothesised that using a recombinant fragment of human SP-D (rfhSP-D) as an adjuvant to exogenous surfactant therapy would reduce ventilator-induced inflammation. We utilised a preterm lamb model of ventilator-associated lung injury. Mechanically ventilated preterm lambs were randomised into control and two treated groups, receiving endotracheal surfactant at 15 min post-delivery. Physiological parameters were measured throughout the experiment. Lung tissue was analysed for changes in alveolar architecture and expression levels of pro-inflammatory cytokines. Bronchioalveolar lavage (BAL) was analysed for SP-D concentration, and inflammatory cells. Intratracheal administration of rfhSP-D improved respiratory outcomes, significantly increased airspace and lung compliance in treated groups. Treated lambs also showed a reduction in lung tissue gene expression of inflammatory cytokines and inflammatory cell counts. Intratracheal administration of rfhSP-D did not negatively impact standard surfactant therapy and appeared to complement it. The administration of rfhSP-D as an adjuvant to standard surfactant therapy effectively reduced lung inflammation supporting the potential therapeutic use of rfhSP-D for preterm infants at risk of developing BPD. We have successfully developed and tested a novel recombinant fragment of human surfactant protein D (rfhSP-D) capable of reducing ventilator-associated lung inflammation in a pre-term lamb model. These results suggest rfhSP-D may be a novel potentially useful therapy for Bronchopulmonary dysplasia (BPD) in combination with currently available surfactant replacement therapies and serves as justification for a first in human clinical trial in mechanically ventilated infants. If successful, rfhSP-D could become a therapeutic candidate to mitigate pulmonary inflammation and improve lung outcomes, potentially offering a novel therapeutic avenue in the prevention or management of BPD.

PMID 42668280
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Rho(D) Immune Globulin